Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Association of low numbers of CD 206‐positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis
Bernard, C, Gibbons, Simon J. , Mann, Inderjit, Froschauer, Lukas, Harbison, Sean, Snape, William J., McCallum, Richard W. , Sarosiek, Irene , Koch, Kenneth L. , Tonascia, James , Hamilton, Frank A., Kendrick, Michael L. , Shen, K. Robert , Pasricha, Pankaj J. , Farrugia, Gianrico , Parkman, Henry P. , Abell, Thomas L. , Hasler, William L. , Nguyen, Linda Anh B. , Gibbons, S J

Mayo Clinic

Neurogastroenterology & Motility | July 15, 2014 | Volume: 26 | Issue: 9 | Pages: 1275-1284

10.1111/nmo.12389 | PMID 25041465 Get It

Abstract Background There is increasing evidence for specific cellular changes in the stomach of patients with diabetic ( DG ) and idiopathic ( IG ) gastroparesis. The most significant findings are loss of interstitial cells of Cajal ( ICC ), neuronal abnormalities, and an immune cellular infiltrate. Studies done in diabetic mice have shown a cytoprotective effect of CD 206+ M2 macrophages. To quantify overall immune cellular infiltrate, identify macrophage populations, and quantify CD 206+ and i NOS + cells. To investigate associations between cellular phenotypes and ICC . Methods Full thickness gastric body biopsies were obtained from non‐diabetic controls (C), diabetic controls ( DC ), DG , and IG patients. Sections were labeled for CD 45, CD 206, Kit, i NOS , and putative human macrophage markers ( HAM 56, CD 68, and EMR 1). Immunoreactive cells were quantified from the circular muscle layer. Key Results Significantly fewer ICC were detected in DG and IG tissues, but there were no differences in the numbers of cells immunoreactive for other markers between patient groups. There was a significant correlation between the number of CD 206+ cells and ICC in DG and DC patients, but not in C and IG and a significant correlation between i NOS + cells and ICC in the DC group, but not the other groups. CD 68 and HAM 56 reliably labeled the same cell populations, but EMR 1 labeled other cell types. Conclusions & Inferences Depletion of ICC and correlation with changes in CD 206+ cell numbers in DC and DG patients suggests that in humans, like mice, CD 206+ macrophages may play a cytoprotective role in diabetes. These findings may lead to novel therapeutic options, targeting alternatively activated macrophages.
The Incidence of Acute Traumatic Tendon Injuries in the Hand and Wrist: A 10-Year Population-based Study
Jong, Johanna P. de, Nguyen, Jesse T., Sonnema, Anne J. M., Nguyen, Emily C., Amadio, Peter C. , Moran, Steven L. , de Jong, Johanna P

Mayo Clinic

Clinics in Orthopedic Surgery | May 22, 2014 | Volume: 6 | Issue: 2 | Pages: 196

10.4055/cios.2014.6.2.196 | PMID 24900902 Get It

Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells
Radhakrishnan, Suresh , Nguyen, Loc T. , Ćirić, Bogoljub , Ure, Daren , Zhou, Bin , Tamada, Koji , Tseng, Su-Yi, Shin, Tahiro, Pardoll, Drew M. , Kyle, Robert A. , Pease, Larry R. , Dong, Haidong , Chen, Lieping , Rodriguez, Moses

Mayo Clinic

The Journal of Immunology | April 21, 2014 | Volume: 170 | Issue: 4 | Pages: 1830-1838

10.4049/jimmunol.170.4.1830 | PMID 12574348 Get It

Abstract A human IgM Ab, serum-derived human IgM 12 (sHIgM12), is identified that binds mouse and human dendritic cells (DC), inducing dramatic immunopotentiation following treatment of the mouse DC in vitro. Competition, transfection, and knockout studies identified the ligand on mouse DC as the costimulatory molecule family member B7-DC. Potent T cell responses are stimulated by Ag-pulsed DC treated with the sHIgM12 Ab in vitro and upon adoptive transfer of Ab-treated Ag-pulsed DC into animals. The multivalent structure of pentameric IgM provides the potential for cross-linking cell surface targets, endowing the soluble Abs with biological potential not normally associated with immune function. The ability of the sHIgM12 Ab to potentiate the immune response is dependent on the multimeric structure of IgM, as bivalent monomers do not retain this property. Furthermore, pretreatment of DC with IgM monomers blocks subsequent potentiation by intact IgM pentamers, an indication that cross-linking of B7-DC on the cell surface is critical for potentiation of Ag presentation. These findings imply that, in addition to known costimulatory roles, B7-DC can function as a receptor for signals delivered by cells expressing B7-DC ligands.
B7-DC/PD-L2 Cross-Linking Induces NF-κB-Dependent Protection of Dendritic Cells from Cell Death
Radhakrishnan, Suresh , Nguyen, Loc T. , Ćirić, Bogoljub , Keulen, Virginia P. Van , Pease, Larry R.

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 178 | Issue: 3 | Pages: 1426-1432

10.4049/jimmunol.178.3.1426 | PMID 17237390 Get It

Abstract Cross-linking cell surface molecules with IgM Abs is a specific approach for activating cells in vitro or in vivo. Dendritic cells (DC) activated with a human B7-DC (PD-L2)-specific IgM Ab can induce strong antitumor responses and block inflammatory airway disease in experimental models, yet the Ab-mediated molecular events promoting these responses remain unclear. Analysis of human or mouse DC treated with the B7-DC cross-linking Ab revealed PI3K-dependent phosphorylation of AKT accompanied by mobilization of NF-κB. Ab-activated DC up-regulated expression of cytokine and chemokine genes in an NF-κB-dependent manner. Importantly, PI3K→AKT→NF-κB activation was found to be indispensable for B7-DC cross-linking Ab-mediated protection of DC from cell death caused by cytokine withdrawal. Although other DC activators similarly protect DC from cell death, a synergy between cross-linking B7-DC and ligating RANK was observed. The parallel signaling events induced in human and mouse DC demonstrate that activation of cells using IgM Ab results in a response governed by a common mechanism and support the hypothesis that B7-DC cross-linking using this Ab may provide beneficial therapeutic immune modulation in human patients similar to those seen in animal models.
Negative Regulation of TCR Signaling by Linker for Activation of X Cells via Phosphotyrosine-Dependent and -Independent Mechanisms
Shapiro, Michael J. , Nguyen, Chau , Aghajanian, Haig , Zhang, Weiguo , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 181 | Issue: 10 | Pages: 7055-7061

10.4049/jimmunol.181.10.7055 | PMID 18981125 Get It

Abstract The activation of T cells and the initiation of an immune response is tightly controlled through the crosstalk of both positive and negative regulators. Two adaptors that function as negative regulators of T cell activation are adaptor in lymphocytes of unknown function X (ALX) and linker for activation of X cell (LAX). Previously, we showed that T cells from mice deficient in ALX and LAX display similar hyperresponsiveness, with increased IL-2 production and proliferation upon TCR/CD28 stimulation, and that these adaptors physically associate. In this study, we analyze the nature of the association between ALX and LAX. We demonstrate that this association occurs in the absence of TCR/CD28 signaling via a mechanism independent of both tyrosine phosphorylation of LAX and the SH2 domain of ALX. Cotransfection of ALX with LAX resulted in LAX tyrosine phosphorylation in the absence of TCR/CD28 stimulation. ALX-mediated LAX phosphorylation depends upon the ALX SH2 domain, which functions to recruit Lck to LAX. We also show that LAX, like ALX, can inhibit RE/AP reporter activation. However, in contrast to its inhibition of NFAT, the inhibition of RE/AP by LAX is independent of its tyrosine phosphorylation. Therefore, it can be concluded that inhibition of signaling events involved in T cell activation by LAX occurs through mechanisms both dependent on and independent of its tyrosine phosphorylation.
Gianotti–Crosti syndrome in a postpartum adult
Brewer, Ann Chang, Michaels, Jason, Hobohm, Dan, DiCaudo, David J. , Nguyen, Xuan Ninh

Mayo Clinic

International Journal of Dermatology | April 17, 2014 | Volume: 54 | Issue: 1 | Pages: 84-85

10.1111/ijd.12006 | PMID 24738477 Get It

Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States
Vergidis, Paschalis , Wheat, L. Joseph , Estes, Lynn L., Caliendo, Angela M. , Baden, Lindsey R. , Wingard, John R. , Assi, Maha, Chandrasekar, Pranatharthi , Shields, Ryan K. , Freifeld, Alison G. , Köhler, Richard, Kleiman, Martin B., Walsh, Thomas J. , Hage, Chadi A. , Estes, Lynn, Razonable, Raymund R. , Baddley, John W. , Norris, Steven J. , Nguyễn, Hồng Quân , Vergidis, Paschalis

Mayo Clinic

Journal of Clinical Microbiology | April 9, 2014 | Volume: 52 | Issue: 6 | Pages: 2199-2201

10.1128/jcm.00285-14 | PMID 24719434 Get It

ABSTRACT Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) was positive. PTZ formulations commonly used in the United States today appear to be a rare cause for false-positive GM results.
Survey of Nongovernmental Organizations Providing Pediatric Cardiovascular Care in Low- and Middle-Income Countries
Nguyen, Nguyenvu, Weinstein, Samuel , Novick, William M. , Jacobs, Marshall L., Massey, Jeremy, Pasquali, Sara K. , Walters, Henry L., Drullinsky, David , Stellin, Giovanni , Tchervenkov, Christo I., Jacobs, Jeffrey P. , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 25, 2014 | Volume: 5 | Issue: 2 | Pages: 248-255

10.1177/2150135113514458 | PMID 24668973 Get It

Background: Nearly 90% of the children with heart disease in low- and middle-income countries (LMICs) cannot access cardiovascular (CV) services. Limitations include inadequate financial, human, and infrastructure resources. Nongovernmental organizations (NGOs) have played crucial roles in providing clinical services and infrastructure supports to LMICs CV programs; however, these outreach efforts are dispersed, inadequate, and lack coordination. Methods: A survey was sent to members of the World Society for Pediatric and Congenital Heart Society and PediHeart. Results: A clearinghouse was created to provide information on NGO structures, geographic reach, and scope of services. The survey identified 80 NGOs supporting CV programs in 92 LMICs. The largest outreach efforts were in South and Central America (42%), followed by Africa (18%), Europe (17%), Asia (17%), and Asia-Western Pacific (6%). Most NGOs (51%) supported two to five outreach missions per year. The majority (87%) of NGOs provided education, diagnostics, and surgical or catheter-based interventions. Working jointly with LMIC partners, 59% of the NGOs performed operations in children and infants; 41% performed nonbypass neonatal operations. Approximately a quarter (26%) reported that partner sites do not perform interventions in between missions. Conclusions: Disparity and inadequacy in pediatric CV services remain an important problem for LMICs. A global consensus and coordinated efforts are needed to guide strategies on the development of regional centers of excellence, a global outcome database, and a CV program registry. Future efforts should be held accountable for impacts such as growth in the number of independent LMIC programs as well as reduction in mortality and patient waiting lists.
Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials
Hawk, Ernest T. , Habermann, Elizabeth B. , Ford, Jean G. , Wenzel, Jennifer , Brahmer, Julie R. , Jones, Lovell A. , Hurd, Thelma C. , Nguyen, Lynne, Ahluwalia, Jasjit S. , Vickers, Selwyn M. , Chen, Moon S. , Rogers, Lisa M. , Fouad, Mona N. , Habermann, Elizabeth

Mayo Clinic

Cancer | March 18, 2014 | Volume: 120 | Issue: S7 | Pages: 1113-1121

10.1002/cncr.28571 | PMID 24643649 Get It

BACKGROUNDTo ensure that National Institutes of Health‐funded research is relevant to the population's needs, specific emphasis on proportional representation of minority/sex groups into National Cancer Institute (NCI) cancer centers' clinical research programs is reported to the NCI.METHODSEMPaCT investigators at 5 regionally diverse comprehensive cancer centers compared data reported to the NCI for their most recent Cancer Center Support Grant competitive renewal to assess and compare the centers' catchment area designations, data definitions, data elements, collection processes, reporting, and performance regarding proportional representation of race/ethnicity and sex subsets.RESULTSCancer centers' catchment area definitions differed widely in terms of their cancer patient versus general population specificity, levels of specificity, and geographic coverage. Racial/ethnic categories were similar, yet were defined differently, across institutions. Patients' socioeconomic status and insurance status were inconsistently captured across the 5 centers.CONCLUSIONSCatchment area definitions and the collection of patient‐level demographic factors varied widely across the 5 comprehensive cancer centers. This challenged the assessment of success by cancer centers in accruing representative populations into the cancer research enterprise. Accrual of minorities was less than desired for at least 1 racial/ethnic subcategory at 4 of the 5 centers. Institutions should clearly and consistently declare their primary catchment area and the rationale and should report how race/ethnicity and sex are defined, determined, collected, and reported. More standardized, frequent, consistent collection, reporting, and review of these data are recommended, as is a commitment to collecting socioeconomic data, given that socioeconomic status is a primary driver of cancer disparities in the United States. Cancer 2014;120(7 suppl):1113–21. © 2014 American Cancer Society.